In addition, Palmen MJ et al. showed that anti-MAC-1 monoclonal antibodies not only reduced myeloid cell tissue infiltration and inflammation but also decreased the recruitment of MDSCs into the tumor site [129]. The gene discussed is ITGB2; the disease is neoplasm.